Acute Ischemic Stroke AIS study: Tenecteplase
Official title ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
ClinicalTrials.gov ID: NCT06320431
What this study is testing
What is Tenecteplase?
an investigational intravenous thrombolytic being studied as a potential treatment for acute ischemic stroke is designed to activate plasminogen and help dissolve blood clots
Also referred to as TNKase, Metalyse.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out which dose of the drug tenecteplase works best for stroke. It also looks at whether to use the drug at all for people on certain blood thinners or those getting a procedure to remove clots.
- Who it's for
- The study is looking for people who have just had an ischemic stroke (a stroke caused by a blood clot).
- What's involved
- Participants will be randomly assigned to receive a standard dose, a lower dose, or no dose of the drug tenecteplase. They will also undergo medical tests and assessments to check their recovery.
- Time commitment
- The study follows participants for 90 days, or until death if it occurs before that time.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- All patients with disabling AIS presenting within 4.5 hours of symptom onset or last known well who may benefit from intravenous thrombolysis (IVT)...
- Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
You likely can't join if
- Any absolute contraindication for IV thrombolysis per current national guidelines.
- Minor stroke patients with non-disabling symptoms.
The study team makes the final eligibility decision.
Where it is enrolling
- Sydney, New South Wales, Australia
- Melbourne, Victoria, Australia
- Calgary, Alberta, Canada
- Edmonton, A, Canada
- Vancouver, British Columbia, Canada
- Winnipeg, Manitoba, Canada
- Greater Sudbury, Ontario, Canada
- Hamilton, Ontario, Canada
- Ottawa, Ontario, Canada
- Toronto, Ontario, Canada
- Charlottetown, Prince Edward Island, Canada
- Saskatoon, Saskatchewan, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Sydney, New South Wales, Australia; Melbourne, Victoria, Australia; Calgary, Alberta, Canada; Edmonton, A, Canada; Vancouver, British Columbia, Canada; Winnipeg, Manitoba, Canada and 6 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.